More recently, in combination with mAbs, CD64/4-1BB CR T cells were shown to have greater tumor killing efficacy and longer persistence (up to day 9 of culture) than did standard CD16-CR T cells and CD32-CR T cells [62]. This evidence concerns the gene FCGR2A and neoplasm.